Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions

Eric A. Meyerowitz,1 Pritha Sen,2,3 Sara R. Schoenfeld,4,4 Tomas G. Neillan,5 Matthew J. Frigault,6 John H. Stone,6 Arthur Y. Kim,2,3 and Michael K. Mansour5,6, for the COVID-19 Immunomodulatory Group

1Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Bronx, New York, USA, 2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, 3Harvard Medical School, Department of Medicine, Boston, Massachusetts, USA, 4Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, and 5Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

(See the Editorial Commentary by Kaiser et al on pages e1144–5.)

In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, viral load peaks early and declines quickly after symptom onset. Severe coronavirus disease 2019 (COVID-19) is marked by aberrant innate and adaptive immune responses with an abnormal cytokine profile and multiorgan system dysfunction that persists well after viral clearance. A purely antiviral treatment strategy may therefore be insufficient, and antiviral agents have not shown a benefit later in the illness course. A number of immunomodulatory strategies are being tested, including corticosteroids, cytokine and anticytokine therapies, small molecule inhibitors, and cellular therapeutics. To date, the only drug to show a mortality benefit for COVID-19 in a randomized, controlled trial is dexamethasone. However, there remains uncertainty about which patients may benefit most and about longer-term complications, including secondary infections. Here, we review the immune dysregulation of severe COVID-19 and the existing data behind various immunomodulatory strategies, and we consider future directions of study.

Keywords. COVID-19; SARS-CoV-2; immunomodulation; hyperinflammatory; cytokine storm.

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a wide spectrum of disease. Among individuals with symptomatic coronavirus disease 2019 (COVID-19), approximately 15%–20% are estimated to develop severe presentations that require supplemental oxygen, including up to 5% who may develop critical illness [1]. Infection fatality rates are population- and age-dependent, with very low rates for children and young adults, but mortality rates >25% for individuals aged >90 years [2]. Areas with rapid surges of infections, associated with delayed access to care, may have higher fatality rates, as was found in Spain and New York City [3, 4]. The explanation for the profound differences in disease severity stratified by age are unknown and likely multifactorial. Current theories include possible increased likelihood of cross-protective cellular immune response from recent infection with common human coronaviruses and age-related changes in immunity, including decreased availability of naive T cells to respond to new viral antigens in older adults [5–7]. Autopsy studies demonstrate that the primary pulmonary pathology is diffuse alveolar damage, with micro- and macrovascular thrombosis [8].

Symptomatic patients typically develop mild symptoms during an acute viral phase, although a subset of patients will progress to severe disease that can last weeks and often requires hospitalization [9–11]. This severe stage is typically marked by immune dysregulation and abnormal inflammatory markers (Figure 1). Higher upper respiratory tract viral loads are associated with more severe presentations [12, 13]. Numerous therapeutic agents are currently under investigation for treatment of COVID-19. During the early phase of the pandemic, many agents were given off-label or in the context of randomized, controlled trials (RCTs). While we will review randomized and nonrandomized series here, it is important to note that only data from high-quality RCTs should change practice in the next phase of the pandemic.

The main therapeutic strategies are direct antiviral and immunomodulatory approaches. To date, remdesivir, a nucleoside analogue that targets the viral RNA-dependent RNA polymerase, has the most supportive data. It showed efficacy when given early to rhesus macaques as well as improvement in time to recovery in the large RCT Adaptive COVID-19 Treatment Trial (ACTT)-1, which compared remdesivir with placebo [14–16]. There was a suggestion of a mortality benefit in patients on supplemental oxygen but not in the intensive care unit (ICU),
with no or minimal survival benefit seen for those with critical
disease [16–18]. A challenge to antiviral therapy for COVID-19 is that patients with severe disease tend to present after 5–7 days of symptoms when viral loads are declining [19, 20].

The only agent yet to show a mortality benefit for COVID-19 is dexamethasone. In a large, open-label, UK-based RCT called Randomized Evaluation of Covid-19 Therapy (RECOVERY), more than 6000 patients were randomized in a 1:2 fashion to dexamethasone or standard of care, with a lower mortality recorded in the dexamethasone group (22.9% vs 25.7%, \( P < .001 \)). The benefit was largest in those who were mechanically ventilated, and there was no benefit among those without

---

**Figure 1.** A, Schematic of the mild illness course for coronavirus disease 2019 (COVID-19) with an effective early innate response and an early, coordinated adaptive immune response. B, Schematic of the severe illness course for COVID-19 where an ineffective innate immune response including an attenuated type I interferon response and poor antigen presentation as well as a late uncoordinated adaptive immune response are associated with poor viral control (higher upper respiratory tract viral load) and proinflammatory, immune dysregulated profile. C-X-C motif chemokine ligand 10 (CXCL10) has been proposed as a possible biomarker for an ineffective specific T-cell response to SARS-CoV-2. Abbreviations: CXCL10, C-X-C motif chemokine ligand 10; IFN, interferon; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; STAT, signal transducer and activator of transcription protein.
that while certain cytokines are elevated in severe COVID-19, interest in IL-6 receptor inhibition as a possible treatment for se-
targeting the IL-6 axis was lifesaving [32] and led to early in-
high levels may result in a signaling cascade, leading to vascular
societies have similarities to cytokine release syndrome (CRS) as-
clinical features of the second phase of severe COVID-19 ill-
receptor, IL-8, IL-10, and TNF-α [30]. The cytokine profile and
nonsurvivors in other markers of inflammation, including IL-2
filing has noted significant differences between survivors and
mechanical ventilation [26], elevated SARS-CoV-2 viremia, and
ample, high IL-6 levels are associated with progression to me-
e1132 •

METHODS

We searched for English-language titles, abstracts, and relevant articles from LitCovid, an electronic literature hub for COVID-
many as IL-6 and IL-1 receptor antagonist as well as re-
duced interferon expression. There is also induction of other
tokines and chemokines, including chemokine ligand 2
(CCL2) and chemokine ligand 8 (CCL8) (which recruit macro-
phages) and CXCL2 and CXCL8 (which recruit neutrophils)
[35]. This “imbalanced host response” is a hallmark of COVID-
19 as the proinflammatory state starts within days after infec-
tion and persists long after viral clearance [35]. This cytokine
milieu recruits and activates neutrophils, macrophages, and T
ymphocytes [36]. In another study of critically ill patients with
COVID-19, circulating CD8+ T lymphocytes showed signif-
icant reductions in cytokines, and natural killer cells had de-
creased intracellular expression of antiviral cytotoxic mediators
zyme A and perforin, consistent with an “exhausted phe-

ACCUMULATING EVIDENCE FOR AN IMMUNE
DYSREGULATION THAT CONTRIBUTE TO SEVERE
COVID-19

Early reports of patients with severe COVID-19 describe marked derangements in inflammatory markers, including el-
volved levels of interleukin-6 (IL-6), ferritin, and C-reactive
protein, each associated with severe outcomes [24, 25]. For ex-
ample, high IL-6 levels are associated with progression to me-
chanical ventilation [26], elevated SARS-CoV-2 viremia, and
longer viral RNA shedding [27–29]. Detailed cytokine pro-
file has noted significant differences between survivors and nonsurvivors in other markers of inflammation, including IL-2
receptor, IL-8, IL-10, and TNF-α [30]. The cytokine profile and
clinical features of the second phase of severe COVID-19 ill-
ness have similarities to cytokine release syndrome (CRS) as-
soiated with chimeric antigen receptor (CAR) T-cell therapy.
In both clinical scenarios, IL-6 that circulates at abnormally
high levels may result in a signaling cascade, leading to vascular
permeability and multisystem organ dysfunction [31]. In CRS,
targeting the IL-6 axis was lifesaving [32] and led to early in-
terest in IL-6 receptor inhibition as a possible treatment for se-
vere COVID-19. More recently, several studies have reported
that while certain cytokines are elevated in severe COVID-19,
There is some overlap between the immune changes associated with this syndrome and those seen in severe COVID-19, including lymphopenia, elevation of various cytokines, and impaired antigen presentation [48].

**CLINICAL DATA FOR IMMUNOMODULATION FOR COVID-19**

Corticosteroids are widely used immunomodulatory agents for a variety of conditions. There was initial hesitation in using them for COVID-19 given an association with prolonged viral shedding when used for other SARS or Middle East respiratory syndrome (MERS) in nonrandomized settings [49]. Steroid use in non-COVID-19–related ARDS has had mixed results, with some studies suggesting a possible mortality benefit; however, steroid use for influenza pneumonia is associated with increased mortality [50, 51]. We identified 531 references on “steroids,” “dexamethasone,” or “methylprednisolone” and included 14 studies (Table 1). While studies have reported mixed efficacy for steroids for COVID-19, they have become standard of care for people with severe or critical COVID-19 based on the RECOVERY trial. Importantly, there is a dearth of data regarding infectious complications of corticosteroids for COVID-19. Additionally, multiple retrospective studies suggest steroid use in mild COVID-19 may be associated with prolonged viral RNA shedding [52–55].

The RECOVERY trial showed a significant mortality benefit for dexamethasone in COVID-19, with the biggest effect in the subgroup that received mechanical ventilation where risk of death was decreased by one-third (29.3% vs 41.4%, with a relative risk of death of 0.64; 95% confidence interval [CI], .51 to .81) [21]. The mortality benefit was more modest for individuals who received supplemental oxygen but did not require mechanical ventilation (23.3% vs 26.2%; rate ratio, 0.82; 95% CI, .72 to .94). Importantly, among those who did not receive supplemental oxygen, there was no benefit seen and, indeed, a trend toward harm (17.8% vs 14.0%; rate ratio, 1.19; 95% CI, .91 to 1.55). The mean time from symptom onset for those not on supplemental oxygen was 6 days compared with 8 days for those with supplemental oxygen and 13 days for those who required mechanical ventilation. In fact, when the subgroup started on steroids before 7 days of symptoms is considered, no mortality benefit was seen. The heterogeneity seen in the results of this trial suggests that a one-size-fits-all approach is not appropriate for treatment of COVID-19. Based on data from the RECOVERY trial, there is strong evidence for steroid administration, preferably dexamethasone, for individuals with COVID-19 who require supplemental oxygen or mechanical ventilation, particularly if they are beyond 7 days of symptom onset. Steroids should be avoided for individuals who do not require supplemental oxygen.

In addition to steroids, numerous other immunomodulatory agents have been used for COVID-19. In an early report from China, it was noted that a IL-6 receptor blocker (tocilizumab) was used to treat 21 patients with severe or critical disease, and rapid and profound improvements in oxygenation, inflammatory markers, and clinical status were reported, generating tremendous interest [68]. Our systematic evaluation identified 412 tocilizumab and 14 sarilumab peer-reviewed articles related to COVID-19, of which 13 are included here (Table 2). A preprint and 2 press releases of major RCTs were also included. The results from the nonrandomized studies are mixed. Importantly, peer-reviewed results from 1 double-blind RCT and 2 open-label RCTs are now available, and additional RCT results are available by preprint and press release. The results from the RCTs are largely concordant, with neither benefit nor an increased risk of secondary infections. One trial reported a benefit because a composite primary endpoint was met, but mortality at 28 days was numerically higher in the tocilizumab arm [69]. These accumulating negative results suggest that COVID-19 is not a true cytokine, specifically IL-6–mediated, storm but rather the result of more complex immune dysregulation. Additional peer-reviewed data are forthcoming; however, at this time, there is no evidence to support the use of IL-6 receptor inhibition for treatment of COVID-19.

Use of other immunomodulatory agents is described in fewer publications. These agents include anakinra (3 studies), baricitinib (2 studies), and ruxolitinib (1 study) (Table 3). Treatment of COVID-19 with the IL-1 receptor antagonism anakinra has been studied, with no RCTs published to date. Two small nonrandomized series have suggested a mortality benefit with this agent, but there are currently no data to support use of this agent outside of a clinical trial [85, 86].

Baricitinib and ruxolitinib are Janus kinase (JAK) inhibitors. Severe COVID-19 is associated with an imbalanced JAK and STAT pathway, with increased relative activity of STAT3 compared with STAT1, contributing to an ineffective antiviral response and a proinflammatory phenotype. Inhibition of JAK–dependent signaling can attenuate overactive STAT3 activity and theoretically ameliorate the immune dysregulation in severe COVID-19 [36, 92]. Baricitinib administration was associated with normalization in the cytokine profile and restoration of circulating lymphocytes levels within a small cohort of hospitalized patients with COVID-19 with fewer than 9 days of symptoms [92]. The results of the ACTT-2 trial were released via a press release, reporting faster time to clinical recovery when baricitinib was added to remdesivir. There are fewer robust data at this time for ruxolitinib. Based on the press release, it is likely that baricitinib will have a role in the treatment of patients with COVID-19, but more details are required from peer-reviewed data. Other kinase inhibitors that are showing preliminary good effect in the reduction of inflammatory parameters and improved oxygenation are selective blockers of Bruton’s tyrosine kinase such as acalabrutinib [93, 94].

Interferon therapy is another immunomodulatory approach being studied for treatment of COVID-19. SARS-CoV-2 is
| Agent [Ref] | Country | Study Design           | Target Population (n) | Endpoint Measured | Outcome and Multivariable Analysis | Infectious Complications | Conclusion or Recommendation | Strength of Evidence |
|------------|---------|------------------------|-----------------------|------------------|-----------------------------------|-------------------------|-------------------------------|--------------------------|
| Dexamethasone [21] | United Kingdom | Open-label, RCT | Hospitalized patients (2104) | Mortality at 28 days | 22.9% vs 25.7% favoring dexamethasone, age-adjusted rate ratio 0.83 (95% CI, .75 to .93) | Not reported | Mortality benefit favoring dexamethasone, strongest effect on those receiving mechanical ventilation | A |
| Hydrocortisone [56] | France | RCT, double-blind | Critically ill patients (76) | Death or persistent mechanical ventilation or high-flow nasal cannula at day 21 | 42.1% vs 50.7% favoring hydrocortisone, difference of proportions –8.6% (95% CI, –24.9% to 7.7%; P = .29) | 37.3% for hydrocortisone and 41.1% for placebo (HR, 0.81; 95% CI, .49 to 1.35; P = .42) | No significant difference in primary outcome; study stopped early (underpowered) | A |
| Methylprednisolone [57] | Brazil | RCT, double-blind | Hospitalized patients with severe or critical COVID-19 (194) | Mortality at 28 days | 32.1% for methylprednisolone vs 38.2% (P = .629) | Not reported | No difference in overall mortality | A |
| Dexamethasone [58] | Brazil | Open-label, RCT | Hospitalized patients with moderate to severe COVID-19 (151) | Ventilator-free days during first 28 days | More ventilator-free days for dexamethasone (difference 2.26; 95% CI, 2 to 4.38; P = .04); no difference in all-cause mortality at 28 days (56.3% vs 61.5%; HR, 0.97; 95% CI, 0.72 to 1.31; P = .88) | 21.9% of dexamethasone and 29.1% of usual care had secondary infections | Dexamethasone was associated with more days off of a ventilator; however, in this study, a mortality benefit was not seen | A |
| Methylprednisolone [59] | Iran | RCT, single-blind | Hospitalized patients with SpO2 <90%, elevated CRP, and elevated interleukin-6, though excluded if acute respiratory distress syndrome, SpO2 <75%, positive procalcitonin or positive troponin (34) | Time to clinical improvement and discharge or death, whichever came first | Methylprednisolone significantly associated with reduced time to primary outcome (11.6 ± 4.8 days vs 17.6 ± 9.8 days, P = .006); mortality rate lower for methylprednisolone group (5.9% vs 42.9%, P < .001) | Not well defined | In a small study with a highly specific group, methylprednisolone showed a benefit | A |
| Methylprednisolone [60] | United States (Michigan) | Single pre-test post-test quasi-experimental study | Hospitalized patients requiring supplemental oxygen (132) | Composite of escalation to ICU or all-cause in-hospital mortality | Primary composite endpoint occurred Not reported in 34.9% vs 54.3% (P = .006) favoring early steroid group; after multivariable adjustment, early corticosteroids were independently associated with a reduction in composite outcome at day 14 (OR, 0.4; 95% CI, .22 to .77) | Not reported | Early steroid use was associated with improved outcomes in this nonrandomized trial | B |
| Methylprednisolone [61] | Spain | Retrospective co-hort study | Hospitalized patients (396) | In-hospital mortality | Patients treated with steroids had lower mortality than those treated with standard of care (13.9% vs 23.9%; HR, 0.51; 95% CI, .27 to .96; P = .044) | Not reported | Steroid use associated with lower B mortality in this nonrandomized trial; the finding persisted after propensity score matching | B |
| Corticosteroids [62] | United States (New York City) | Retrospective co-hort study | Hospitalized patients; compared those who received steroids within 48 hours of admission compared with those who never received steroids (140) | Composite of in-hospital mortality or in-hospital mechanical ventilation | Early glucocorticoids were not associated with decreased in-hospital mortality, though among subgroup with CRP >2.0 mg/dL was associated with reduced mortality or mechanical ventilation (adjusted OR, 0.20; 95% CI, .06 to .67) | Not reported | Steroid use was not associated with improved outcomes overall; among those with elevated CRP, steroid use was associated with improved outcomes | B |
| Agent [Ref]          | Country | Study Design          | Target Population (n) | Endpoint Measured                  | Outcome and Multivariable Analysis                                                                 | Infectious Complications                                                                 | Conclusion or Recommendation                                                                 | Strength of Evidence |
|----------------------|---------|-----------------------|-----------------------|------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------|
| Corticosteroids [63] | China   | Retrospective cohort study | Hospitalized patients (158) | In-hospital mortality | Patients who received corticosteroids had higher mortality (45.6% vs 11.5%, P < .0001), after propensity matching, there was no difference in mortality | There were more nosocomial infections among those treated with steroids (70% vs 2.9%, P = .02) | This nonrandomized trial found no benefit of steroids for treatment of COVID-19           | B                   |
|                      |         |                       |                       | mortality                       |                                                                                                      |                                                                                          |                                                                                           |                     |
| Corticosteroids [64] | Italy   | Retrospective cohort study | Hospitalized patients with severe COVID-19 (170) | Mortality at day 30 from hospital admission | 35% in corticosteroid group and 31% in nonsteroid group died within 30 days of hospital admission; multivariable analysis adjusted OR, 0.59; 95% CI, 0.20 to 1.74; P = .33 | 17% of overall cohort had bacterial superinfections; hazard was higher for those who received steroids but not statistically significant (HR, 1.55; 95% CI, 95 to 2.55; P = .08) | This nonrandomized trial found no mortality benefit of corticosteroids for severe COVID-19 | B                   |
|                      |         |                       |                       | mortality                       |                                                                                                      |                                                                                          |                                                                                           |                     |
| Corticosteroids [55] | China   | Retrospective cohort study | Hospitalized patients (126) | Hospital length of stay | After matching, among nonsevere group, steroid use associated with increased length of stay (19.0 days vs 11.5 days, P < .001); among severe group, no significant difference in length of stay (14.0 days vs 16.0 days, P = .883) | Unable to report infection rates, but antibiotic use higher among those who received steroids (P < .001) | This nonrandomized trial found no benefit of steroid use for COVID-19 and found longer hospital stay for nonsevere patients who received steroids compared with matched nonsteroid recipients | B                   |
|                      |         |                       |                       | mortality                       |                                                                                                      |                                                                                          |                                                                                           |                     |
| Corticosteroids [65] | United States (New York City) | Retrospective cohort study | Hospitalized patients with severe COVID-19 (SpO2/ fO2 <440) (60) | Composite outcome of ICU transfer, intubate, or death | In adjusted analysis, those who received steroids were less likely to have had a primary outcome (adjusted HR, 0.15; 95% CI, 0.07 to .33; P < .001) | Not reported | In this nonrandomized study of patients with severe COVID-19, steroid administration was associated with improved outcomes | B                   |
|                      |         |                       |                       | mortality                       |                                                                                                      |                                                                                          |                                                                                           |                     |
| Corticosteroids [66] | China   | Retrospective cohort study | Hospitalized patients with severe (requiring supplemental oxygen) or critical (shock, mechanical ventilation, or ICU-level care) COVID-19 (531) | In-hospital mortality | In multivariable analysis, steroid use was independently associated with in-hospital mortality (HR, 1.77; 95% CI, 1.08 to 2.89; P = .023) | Not reported | In this nonrandomized study of severely and critically ill patients with COVID-19, steroid use was associated with an increased risk of death | B                   |
|                      |         |                       |                       | mortality                       |                                                                                                      |                                                                                          |                                                                                           |                     |
| Methylprednisolone [67] | China   | Retrospective cohort study | Hospitalized patients with severe or critical COVID-19 (140) | Progression from severe to critical illness | In multivariate analysis, methylprednisolone was associated with less risk of progression to critical illness (OR, 0.054; 95% CI, 0.017 to .173; P < .001); in a subgroup analysis, the finding held for individuals aged <65 years but not for those aged >65 years | Not reported | In this nonrandomized study, steroid use was associated with less progression to critical illness | B                   |

**Abbreviations:** CI, confidence interval; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; fO2, fraction of inspired oxygen; HR, hazard ratio; ICU, intensive care unit; OR, odds ratio; RCT, randomized, controlled trial; Ref, reference; SpO2, peripheral capillary oxygen saturation.

*a* Number of patients in study who received immunomodulatory therapy.

*b* Strength of evidence graded as: A = from a randomized, controlled trial; B = from a nonrandomized study.
| Reference | Country | Comedications | Study Design | Target Population (n) | Endpoint Measured | Outcome and Multivariable Analysis | Infectious Complications | Conclusion or Recommendation | Strength of Evidence |
|-----------|---------|----------------|--------------|----------------------|------------------|-----------------------------------|-------------------------|------------------------------|--------------------------|
| 70        | United States (Boston) | Steroids (10%), RDV (~33%), HCQ (4%) | RCT, double-blind | Hospitalized patients with 2 of the following: fever, pulmonary infiltrates, need for supplemental oxygen and 1 of the following: elevated CRP, D-dimer, ferritin, or lactate dehydrogenase (LDH) (161) | Intubation and mortality at day 28 | 10.5% in TCZ group vs 12.5% in placebo group had been intubated or died by day 28 (HR, 0.83; 95% CI, 38 to 181; P = .84) | There were fewer infectious complications in the TCZ group (81% vs 171%, P = .03) | This double-blind RCT does not support using TCZ for patients with severe COVID-19 | A |
| 71        | France | Azithromycin (~20%), HCQ (~8%), steroids (~30%, more in usual care arm) | RCT, open-label | Hospitalized patients with moderate, severe, or critical COVID-19 (63) | Need for ventilation and mortality | Suggestion of benefit for TCZ at day 14; however, mortality at day 28 11.1% for TCZ vs 11.9% for standard of care (aHR, 0.92; 95% CI, .33 to 2.53) | Secondary infections reported in 3.7% for TCZ vs 20.9% for standard-of-care group | This open-label RCT found no mortality benefit for TCZ at 28 days | A |
| 72        | Italy | Azithromycin (~20%), DRV/c (~30%), or LPV/r (~40%) | RCT, open-label | Hospitalized patients with PaO2/fiO2 of 200–300 and fever or elevated CRP (60) | Admission to ICU or death by day 14 | 28.3% for TCZ vs 27.0% met primary outcome; mortality at day 30 was 3.3% for TCZ vs 1.6% | Secondary infections reported in 1.7% of TCZ vs 6.3% | This open-label RCT found no benefit of TCZ | A |
| 69        | Multinational | Steroids and various antivirals used in 80% | RCT, double-blind | Hospitalized patients with SpO2 ≤94% on ambient air (349) | Composite outcome occurred in 12.0% for TCZ vs 19.3% for placebo (aHR, 0.56; 95% CI, .30 to .97; P = .036); mortality at day 28 was numerically higher in the TCZ arm (10.4% vs 6.6%, weighted difference, 2%; 95% CI, –5.2% to 7.8%) | Serious infections reported in 5.2% in TCZ and 7.1% placebo | This double-blind RCT met its primary composite endpoint; however, there was numerically higher mortality at 28 days in the TCZ arm | A (report not peer reviewed) |
| 73        | United States and Europe | No details to date | RCT, double-blind | Hospitalized patients with severe COVID-19 (1–225) | Improved clinical status at day 28 and mortality | No difference in clinical status at day 28 (odds ratio, 1.19; 95% CI, 1.01 to 2.1; P = .03); mortality at day 28 was numerically higher in the TCZ arm (11.2% vs 9.7%, 95% CI, –1.2% to 3.8%; P = .064); mortality at day 30 was 3.3% for TCZ vs 1.6% | No difference in secondary infections between the groups (38.3% vs 40.6%) | This double-blind RCT found no benefit of TCZ for severe COVID-19 | A (though data peer reviewed) |
| 74        | United States (multiple sites) | No details to date | RCT, double-blind | Hospitalized patients with severe-COVID-19 (~1200) | Improved clinical status and mortality | Per press report: “did not meet its primary and key secondary endpoints” | Not reported to date | This double-blind RCT found no benefit for sarilumab | A (though data peer reviewed) |
| 75        | Italy | HCQ and LPV/r | Retrospective cohort study | Hospitalized patients with RR ≤30, SpO2 ≤93% on ambient air, or PaO2 / FiO2 ≤300; critical patients excluded (82) | Survival rate | 3.2% vs 47.8% mortality favoring TCZ (aHR, 0.039; 95% CI, .004 to .347; P = .004) | No secondary infections reported in either group | This nonrandomized study in patients with severe COVID-19 found TCZ was associated with decreased mortality | B |
| 76        | Italy | HCQ + LPV/r or RDV | Retrospective cohort study | Hospitalized patients with bilateral pulmonary infiltrates and CRP >1 mg/dL, interleukin-6 >40 mg/L, D-dimer >1.5 mg/L, or ferritin >500 ng/mL with severe or critical COVID-19 (74) | Survival rate | TCT use associated with improved survival (HR, 0.499; 95% CI, .262 to 0.952, P = .039); benefit highest in critical illness, no severe disease | 32.4% of TCZ-treated patients had secondary infections, but no comparison reported for standard-of-care group | This nonrandomized study found TCZ was associated with decreased mortality; many secondary infections were reported, but no comparison was available with the standard-of-care group | B |
Table 2. Continued

| Reference | Country            | Comedations                          | Study Design        | Target Population | Endpoint Measured                     | Outcome and Multivariable Analysis | Infectious Complications | Conclusion or Recommendation | Strength of Evidence |
|-----------|--------------------|--------------------------------------|---------------------|-------------------|---------------------------------------|------------------------------------|--------------------------|---------------------------|--------------------------|
| 77        | United States      | 25% received steroids, 23% HCQ, 3% RDV | Retrospective cohort study | Intubated patients (78) | Survival probability after intubation | Mortality at day 28 lower for TCZ-treated patients at 18% vs 36% (P = 0.01; aHR, 0.54; 95% CI, 35 to 84) | TCZ-treated patients more likely to have superinfection (84% vs 26%, P < 0.001) | This nonrandomized study found TCZ use was associated with decreased mortality but increased rate of superinfections in a critically ill cohort | B                       |
| 78        | United States      | HCQ + azithromycin in >90%, steroids ~40%, RDV ~10% | Retrospective case-control study | Hospitalized patients with severe or critical COVID-19 (96) | Overall mortality rate | Mortality rates 52% vs 62% (P = 0.09); excluding intubated patients 6% vs 27% (P = 0.04), favoring TCZ | Bacteremia more common in control group (23.7% vs 12.5%, P = 0.04), fungemia similar (3% vs 4%, P = 0.7) | This nonrandomized study found TCZ was associated with a lower mortality rate among nonintubated patients with COVID-19 | B                       |
| 79        | Spain              | HCQ (98%), LPV/r (82%), azithromycin (74%), interferon-β (28%), steroids (19%) | Retrospective cohort study | Hospitalized patients with fever or need for supplemental oxygen and elevated CRP, D-dimer, or ferritin (98) | Intubation or death | 11.4% vs 20.1% of patients required intubation or died, favoring TCZ | Rates of secondary bacterial infections were similar (12.5% vs 10.3%, P = 0.57) | This nonrandomized study found TCZ was associated with lower rates of intubation or death with similar rates of secondary bacterial infections | B                       |
| 80        | Italy              | HCQ + LPV/r                          | Retrospective cohort study | Hospitalized patients with bilateral pulmonary opacities and RR ≥3.0, SpO2 <93% on ambient air, or PaO2/FiO2 ≤200 | Survival rate | 7.7% vs 50% mortality favoring TCZ, aHR for death was 0.057 (95% CI, 0.17 to 0.87; P < 0.001) | No secondary infections observed | This nonrandomized study found TCZ was associated with lower mortality in patients with COVID-19 | B                       |
| 81        | United States      | Steroids (66%), HCQ + azithromycin (>90%) | Retrospective cohort study | Hospitalized patients with COVID-19 in the ICU (134) | Survival rate | 46% vs 56% mortality favoring TCZ (aHR, 0.74; 95% CI, 0.57 to 1.00) | 13% vs 11% bacteraemia | This nonrandomized study found a trend toward improved mortality when TCZ was given for critical COVID-19 | B                       |
| 82        | United States      | RDV in around one-third, TCZ patients more likely to get HCQ than controls (57% vs 20%, P = 0.001) | Retrospective cohort study | Hospitalized patients with severe COVID-19 with progressive hypoxemia with elevated D-dimer ≥2 mg/L, CRP >100 mg/dL or ferritin >600 µg/L | Secondary infections and mortality | Mortality was higher among those who received TCZ (38% vs 23%, P = 0.03) | Late-onset infections were more commonly seen in the TCZ group (23% vs 8%, P = 0.013) | This nonrandomized trial found TCZ was associated with increased mortality and increased late-onset infections | B                       |
| 83        | Italy              | LPV/r (or DRVc) and HCQ | Retrospective case-control study | Hospitalized patients with worsening oxygen requirement, elevated CRP and another in a list of abnormal laboratory results (64) | Mortality rates | Mortality was not associated with TCZ treatment (aHR, 0.82, 95% CI, 0.23 to 2.70; P = 0.58) | The rate of secondary infections was not different between the groups, 31% for TCZ vs 39% (HR, 0.71; 95% CI, 0.38 to 1.32, P = 0.28) | This nonrandomized trial found no mortality benefit for TCZ, with a similar amount of secondary infectious complications | B                       |

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; DRVc, darunavir/cobicistat; FiO2, fraction of inspired oxygen; HCQ, hydroxychloroquine; HR, hazard ratio; ICU, intensive care unit; LPV/r, lopinavir/ritonavir; PaO2, partial pressure of oxygen; PCT, randomized, controlled trial; RDV, remdesivir; RR, respiratory rate; SpO2, peripheral arterial oxygen saturation; TCZ, tocilizumab.

*a* = number of patients in study who received immunomodulatory therapy.

*b* = strength of evidence graded as: A = from a randomized, controlled trial; B = from a nonrandomized study.
| Agent [Ref] | Country | Study Design | Target Population (n)a | Endpoint Measured | Outcome and Multivariable Analysis | Infectious Complications | Conclusion or Recommendation | Strength of Evidenceb |
|-------------|---------|--------------|------------------------|-------------------|-----------------------------------|------------------------|------------------------------|------------------------|
| Anakinra [85] | Italy | Retrospective cohort study | Hospitalized patients with moderate to severe COVID-19 with hyperinflammation, with C-reactive protein ≥100 mg/dL or ferritin ≥900 ng/mL (29) | Survival rates | Mortality was 10% in the anakinra group and 44% in the standard treatment group (P = .003) | Bacteremia in 14% anakinra vs 13% standard treatment | In this small nonrandomized study, anakinra was associated with decreased mortality among patients with severe COVID-19 and laboratory evidence of inflammation | B |
| Anakinra [86] | France | Retrospective cohort study | Hospitalized patients with severe COVID-19 (52) | Composite of intensive care unit admission, need for mechanical ventilation, or death | Composite less common in those who received anakinra compared with historical controls (25% vs 73%; HR, 0.22; 95% CI, 0.11 to 0.41; P < .0001) | No secondary bacterial infections documented | In this nonrandomized study, anakinra was associated with reduced mortality compared with a historical control | B |
| Anakinra [87] | United States (Los Angeles) | Retrospective cohort study | Hospitalized patients with COVID-19 with progressive hypoxemia and bilateral pulmonary infiltrates (52) | Survival rates | Mortality was lower in anakinra group (22%) than TCZ group (46.2%) after adjustment (adjusted HR, 0.46; 95% CI, 0.18 to 1.20; P = .11) | Not reported | In this nonrandomized study that compared anakinra with TCZ administration, there was no statistically significant difference in mortality between the 2 agents | B |
| Baricitinib [88] | Global (National Institutes of Health) | RCT, double-blind | Hospitalized patients with COVID-19 (~500) | Time to clinical recovery | Study met primary endpoint | Not reported | In this double-blind, randomized, controlled trial, baricitinib improved time to clinical recovery when added to remdesivir | A |
| Baricitinib [89] | Italy | Retrospective cohort study | Hospitalized patients with moderate COVID-19 with radiographic pneumonia, SpO₂ >92% on room air, and PaO₂/FiO₂ 100-300 (113) | Mortality rate at 2 weeks | Lower mortality in baricitinib arm (0% vs 6.4%, P = .010) | Not reported | In this nonrandomized study, baricitinib was associated with improved mortality at 2 weeks compared with historical controls; polymerase chain reaction positivity was significantly lower at day 14 for those who received baricitinib (12.5% vs 40%) | B |
| Baricitinib [90] | Spain | Prospective cohort study | Hospitalized patients with severe COVID-19 with PaO₂/FiO₂ <200 (62) | Improved SpO₂/FiO₂ | A greater improvement in SpO₂/FiO₂ was seen for those who received baricitinib | Two bacteremias in control group, none in baricitinib group | In this nonrandomized study, baricitinib improved oxygenation when added to steroids and multiple other “standard therapies” compared with those therapies alone | B |
| Ruxolitinib [91] | China | RCT, single-blind | Hospitalized patients with severe COVID-19 (20) | Time to improved clinical status, mortality | Patients who received ruxolitinib had a numerically shorter time to clinical improvement (12 days vs 15 days; HR, 1.67; 95% CI, 0.84 to 3.34; P = .15); mortality at day 28 was 0% for ruxolitinib vs 14.3%, but cumulative incidence of death was the same between the groups | Two secondary infections in control group and none in ruxolitinib group | This small RCT found numerically faster but not statistically significant clinical improvement for those who received ruxolitinib | A |

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; FiO₂, fraction of inspired oxygen; HR, hazard ratio; RCT, randomized, controlled trial; Ref, reference; SpO₂, peripheral capillary oxygen saturation; TCZ, tocilizumab.

a = number of patients in study who received immunomodulatory therapy.

b Strength of evidence graded as: A = from a randomized, controlled trial, B = from a nonrandomized study.
### Table 4. Series Reporting Data for Interferon for Treatment of Coronavirus Disease 2019

| Type of IFN | Country | Comedications | Study Design | Target Population (n) | Endpoint Measured | Outcome and Multivariable Analysis | Infectious Complications | Conclusion or Recommendation | Strength of Evidence |
|------------|---------|---------------|-------------|----------------------|------------------|-----------------------------------|-------------------------|-----------------------------|-------------------|
| INF-β [101] | Hong Kong | LPV/r + ribavirin, 7% steroids | RCT, open-label | Hospitalized patients with COVID-19 and National Early Warning Score ≥ 2, ≥14 days (86) | Time to negative PCR, mortality | Combination therapy associated with significantly shorter median time to PCR negativity (7 days vs 12 days; HR, 4.37; 95% CI, 1.86 to 10.24; P = .001); no patients died in either arm | Not reported | In this RCT where treatments were started around day 5 after symptom onset in a relatively mild cohort, combination therapy with INF-β, ribavirin, and LPV/r showed faster viral clearance compared with LPV/r only | A |
| INF-β [102] | Iran | HCQ + LPV/r or ATV/r, 62% received steroids | RCT, open-label | Hospitalized patients with severe COVID-19 with hypoxemia, hypotension, renal failure, neurologic change, thrombocytopenia, or severe gastrointestinal symptoms | Time to clinical improvement | No difference in time to clinical improvement between the groups, 9.7 days for INF vs 8.3 days (P = .95; HR, 1.10; 95% CI, 0.64 to 1.87); however, day 28 mortality lower in INF group (19% vs 43.6%, P = .015) when adjusted for IVIG and steroid administration effect remained (aHR, 0.37; 95% CI, 0.16 to 0.87; P = .024) | No difference in time to discharge between the groups, 12.9% deaths for INF vs 11.0% for controls, no difference | Not reported | In this RCT, INF-β did not increase time to clinical improvement but was associated with lower mortality even after controlling for steroid use; INF was started a mean of 11.7 days after symptom onset | A |
| INF-β [103] | Iran | LPV/r or ATV/r + HCQ, steroids in nearly 30% | RCT, open-label | Hospitalized patients with severe COVID-19 (33) | Time to improve clinical status | Time to clinical improvement was shorter for the INF group (9 days vs 11 days; P = .002; aHR, 3.41; 95% CI, 1.33 to 8.72) | No nosocomial infections in 3% vs 18% favoring INF | In this small RCT, INF-β1b was associated with reduced mortality among a cohort with severe COVID-19; started at mean 7 days of symptom onset | A |
| INF-β [104] | Multinational (World Health Organization) | LPV/r or “local standard of care” | RCT, open-label | Hospitalized patients with COVID-19 (2050) | Mortality | 12.9% deaths for INF vs 11.0% for controls, no difference | Not reported | In this open-label RCT, INF-β1a was not associated with improved outcomes; there are no data yet available about when in the illness course the treatment was given | A |
| INF-α [105] | China | Arbidol | Retrospective cohort study | Hospitalized patients with moderate COVID-19 (83) | Time to negative upper respiratory tract PCR test | IFN was associated with accelerated viral clearance from the upper respiratory tract by ~7 days (P = .002) | Not reported | In this nonrandomized study, INF-α2b therapy was associated with more rapid viral clearance from the upper respiratory tract | B |
| INF-α [106] | China | LPV/r + chloroquine | Prospective cohort study | Hospitalized patients with COVID-19 (761) | Time to discharge and mortality | Mortality reported much lower in IFN group | Not reported | In this highly confounded nonrandomized study where there were significant age and comorbidity differences between the groups, INF-α2b was associated with improved outcomes | B |
| INF-α [107] | China | LPV/r or arbidol | Retrospective cohort study | Hospitalized patients with COVID-19 (242) | Mortality | Early IFN therapy was associated with lower mortality (aHR, 0.10; 95% CI, 0.02 to 0.50); among the 26 who received late IFN, there was increased mortality (aHR, 2.30; 95% CI, 0.64 to 8.27 compared with no IFN therapy) | Not reported | In this nonrandomized study, early INF-α2b (defined as given within 48 hours of admission) was associated with reduced mortality | B |

Abbreviations: aHR, adjusted hazard ratio; ATV/r, atazanavir with ritonavir; CI, confidence interval; COVID-19, coronavirus disease 2019; HCQ, hydroxychloroquine; HR, hazard ratio; IFN, interferon; IVIG, intravenous immunoglobulin; LPV/r, lopinavir with ritonavir; PCR, polymerase chain reaction; RCT, randomized, controlled trial; Ref, reference.

an = number of patients in study who received immunomodulatory therapy.

bStrength of evidence graded as: A = from a randomized, controlled trial; B = from a nonrandomized study.
sensitive to type I interferons in vitro, with markedly decreased viral replication [95]. SARS-CoV-2 evades the interferon response, and insufficient interferon stimulation is seen in patients with severe COVID-19 [96]. Taken together, this observation has led to the hypothesis that early type I interferon administration might help limit viral replication. The MERS-CoV Infection Treated with a Combination of洛匹那韦- ritonavir and Interferon Beta-1b (MIRACLE) trial for MERS, which is the first RCT published for treatment of either SARS or MERS, found that interferon-β1b was associated with lower mortality in a prespecified subgroup when it was given within 7 days of symptom onset but had no effect later in the illness course [97]. It is important to note that viral load dynamics are different between MERS-CoV and SARS-CoV-2, with upper respiratory tract viral peak around 7–10 days for MERS-CoV and earlier for SARS-CoV-2 infection [98]. Given the earlier viral phase for SARS-CoV-2 and the fact that most people present 4–7 days after symptom onset when viral loads are already declining, it remains to be seen whether interferons have a role in the treatment of COVID-19 [99, 100].

Of 418 papers related to SARS-CoV-2 and interferons, 8 are included here (Table 4). An open-label RCT evaluated treatment with triple therapy (interferon-β1b, ribavirin, and lopinavir/ritonavir) against lopinavir/ritonavir monotherapy and found that the interferon-treated group had faster viral clearance from nasopharyngeal swabs of 7 days vs 12 days ($P = .001$) [101]. This striking result is notable since no other randomized treatment study has demonstrated such impact, including a remdesivir study [14], and suggests that specific immune augmentation may have a potent anti-SARS-CoV-2 viral effect. Preliminary data from the large World Health Organization–sponsored solidarity trial suggest interferon-β1b administration was not associated with a change in mortality; however, there is no information about the timing of administration [19]. Currently there are insufficient data to support interferon use for COVID-19 outside of a clinical trial, and further study, particularly early in the disease, is needed. Given the finding of autoantibodies to some type I interferons (most commonly interferon-α) in severe COVID-19, interferon-β formulations may be more likely to have effect than interferon-α [39].

CONCLUSIONS

Severe COVID-19 is marked by a protracted course with evidence of immune dysregulation and, at times, multisystem organ dysfunction. Several proposed strategies for treatment include antiviral agents and immunomodulatory therapeutics. Since SARS-CoV-2 viral loads peak around the time of symptom onset and patients with severe immune dysregulation often present 5–7 days later, an approach that is exclusively antiviral may not be sufficient for all patients. Antivirals and stimulators of innate antiviral response (ie, interferons) may be most likely to show benefit early in the disease course when viral loads are highest, likely within 7 days of symptom onset and sooner if possible. While early hypotheses proposed that the second phase of the severe COVID-19 illness course might be similar to cytokine release syndrome, immune profiling has revealed a complex immune dysregulation with a central role for the type I interferon response. Strategies to attenuate this imbalanced response, including steroids and targeted therapies are all being actively studied.

Given the marked heterogeneity of COVID-19 clinical presentations, therapeutic approaches will likely need to be tailored to individual patients, and a one-size-fits-all approach may not provide optimal benefit. Potential therapeutic approaches will need to identify the right therapy, dose, patient, and proper timing in relation to the disease course. To define these specific treatments, data from well-performed RCTs are needed that include details about timing of administration of agents in the COVID-19 illness course.
References

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239–42.

2. Levin AT, Hanage WP, Onguru-Boaity N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for Covid-19: systematic review, meta-analysis, and public policy implications. medRxiv 2020. doi: 10.1101/2020.07.23.20160895.

3. Kenyon C. COVID-19 infection fatality rate associated with incidence—a population-level analysis of 19 Spanish autonomous communities. Biology 2020; 9:128.

4. Yang W, Kandula S, Huynh M, et al. Estimating the infection fatality risk of COVID-19 in New York City during the spring 2020 pandemic wave. medRxiv 2020. doi: 10.1101/2020.06.27.20141689.

5. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020; 181:1489–501.e15.

6. Sagar M, Reiffer K, Rossi M, et al. Recent endemic coronavirus infection is associated with less severe COVID-19. J Clin Invest 2020; 143:380. doi: 10.1172/JCI134380.

7. Rydzynski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020; 183:996–1012.e19.

8. Borzućk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol 2020; 1–13.

9. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172:577–82.

10. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–20.

11. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med 2020; 383:1757–66.

12. Maglèry B, Westblad LF, Trezbacka A, et al. Impact of severe acute respiratory syndrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019 [manuscript published online ahead of print 30 June 2020]. Clin Infect Dis 2020;ciaa851. doi:10.1093/cid/ciaa851.

13. Westblad LF, Brar G, Pintohe LC, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell 2020; 38:661–671.e2.

14. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395:1569–78.

15. Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020; 585:273–6.

16. Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med 2020; 383:994.

17. Spinner CD, Gottlieb RL, Criner GJ, et al.: GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324:1048–57.

18. Pan H, Liao R, Abdool Karim Q, et al. Repurposed antiviral drugs for COVID-19, interim WHO SOLIDARITY trial results. medRxiv 2020. doi: 10.1101/2020.05.20.2009817.

19. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020; 20:565–74.

20. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020; 20:656–7.

21. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report [manuscript published online ahead of print 17 July 2020]. N Engl J Med 2020;NEJMoa2021436. doi:10.1056/NEJMoa2021436.

22. Turki A, Vetrone LM, Papa A. Anti-TNF-a agents in inflammatory bowel disease and course of COVID-19. Inflamm Bowel Dis 2020; 26:e73.

23. Gianfrancesco M, Hryck KL, Al-Adey S, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020; 79:859–66.

24. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.

25. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323:1061–9.

26. Herold T, Jurinovic V, Arrentie C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 2020; 146:128–36.e4.

27. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis 2020; 71:1937–42.

28. Lin A, He Z-B, Zhang S, Zhang J-G, Zhang X, Yan W-H. Early risk factors for the duration of SARS-CoV-2 viral positivity in COVID-19 patients. Clin Infect Dis 2020; 71:2061–5.

29. Petrelli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369:m1966.

30. Wang Y, Lu X, Chen H, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020; 201:1430–4.

31. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368:473–4.

32. Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol 2019; 74:3099–108.

33. Kox M, Waalders NB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA 2020; 324:1565–7.

34. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and public policy implications. medRxiv 2020; 2020.05.06.20098178.

35. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Intramyocardial host response to SARS-CoV-2 drives development of COVID-19. Cell 2020; 181:1036–1045.e9.

36. Spinelli FR, Conti F, Gadina M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol 2020; 5:eabc3567.

37. Mazzoni A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest 2020; 130:4694–703.

38. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020; 370:eaba4570.

39. Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370:eaba4585.

40. Xia H, Cao Z, Xie X, et al. Evasion of type I interferon by SARS-CoV-2. Cell Rep 2020; 33:108234.

41. Lee X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 2020; 11:3810.

42. Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer M, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ 2020; 17:1–10. doi: 10.1038/s41418-020-00633-7.

43. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020; 10:537–40.
44. Verdolin L, Maaza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395:1771–8.

45. Dufort EM, Koumans EH, Chow EJ, et al.; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020; 383:347–58.

46. Feldstein LR, Rose EB, Horwitz SM, et al.; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383:334–46.

47. Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection—United Kingdom and United States, March-August 2020. MMWR Mortal Mortal Wkly Rep 2020; 69:1450–6.

48. Carter MJ, Fish M, Jennings A, et al. Peripheral immunopathologies in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med 2020; 26:1701–7.

49. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395:473–5.

50. Zayed Y, Barbarawi M, Ismail E, et al. Use of glucocorticoids in patients with acute respiratory distress syndrome: a meta-analysis and trial sequential analysis. J Intensive Care 2020; 8:43.

51. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on COVID-19 patients. J Clin Endocrinol Metab 2020; 105:dgaa627.

52. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease in adults associated with COVID-19 in Italy. Circulation 2020; 142:1848–53.

53. Hu Z, Lv Y, Xu C, et al. Clinical use of short-course and low-dose corticosteroids as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled trial. NEJMoa20208836.

54. Huang R, Zhu C, Wang J, et al. Corticosteroid therapy is associated with the clinical worsening in patients hospitalized with COVID-19 pneumonia. J Infect Dis 2020; 222:1198.

55. Rossotti R, Travi G, Ughi N, et al. Safety and efficacy of anti-Il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect 2020; 81:e11–7.

56. Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. J Infect Dis 2020; 221:954–56.

57. Rodríguez-Baño J, Pachón J, Carratalà J, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COV19) [manuscript published online ahead of print 11 July 2020]. Clin Infect Dis 2020;ciaa954. Available at: https://www.roche.com/investors/updates/inv-update-2020-07-29.htm. Accessed 17 October 2020.

58. Hip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—an observational study. PLoS One 2020; 15:e0237693.

59. Tribouilloy C, Maurin E, Dubrez D, et al. Hydroxychloroquine and azithromycin for treatment of mild-to-moderate COVID-19 patients: multicentre, retrospective study with a complete follow-up. EClinicalMedicine 2020; 25:100459.

60. Verdoni L, Mazza A, Gervasoni A, et al. Tocilizumab in COVID-19 patients. NEJMoa20208836.

61. Sommers EC, Eschenauer GA, Troost JP, et al. Tocilizumab in nonventilated patients hospitalized with COVID-19. JAMA 2020; 324:1–11.

62. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020; 76:65–8.

63. Capra R, Travi G, Ughi N, et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect 2020; 81:e11–7.

64. Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—an observational study. PLoS One 2020; 15:e0237693.

65. Tribouilloy C, Maurin E, Dubrez D, et al. Hydroxychloroquine and azithromycin for treatment of mild-to-moderate COVID-19 patients: multicentre, retrospective study with a complete follow-up. EClinicalMedicine 2020; 25:100459.
90. Rodriguez-Garcia JL, Sanchez-Nieves G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuet JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study [manuscript published online ahead of print 6 October 2020]. Rheumatology 2020; keaa587. doi:10.1093/rheumatology/keaa58

91. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020; 146:137–46.e3.

92. Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in severe COVID-19 patients. J Clin Invest 2020; 130:6409–16.

93. Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135:1912–5.

94. Roschewski M, Lionakis MS, Sharpm JF, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020; 5:eabb0110.

95. Sallard E, Lesure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 2020; 178:104791.

96. Wang N, Zhan Y, Zhu L, et al. Retrospective multicenter study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe 2020; 28:455–46.e2.

97. Arabi YM, Asiri AY, Assiri AM, et al.; Saudi Critical Care Trials Group. Interferon beta-1b and lopinavir-ritonavir for Middle East respiratory syndrome. N Engl J Med 2020; 383:1645–56.

98. Rodrigo-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy [manuscript published online ahead of print 24 September 2020]. J Viral Hepat 2020; ciaa1298. doi:10.1111/jvh.13410

99. Marchese V, Crosato V, Gulletta M, et al. Strongyloides infection manifested as COVID-19. J Allergy Clin Immunol 2020; 146:137–46.e3.

100. McCarthy CP, Murphy S, Jones-O’Connor M, et al. Corticosteroid-induced osteonecrosis in COVID-19: a call for caution. J Bone Miner Res 2020; 35:1828–9.

101. Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018; 131:121–30.

102. White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose coronavirus 2019–associated invasive fungal disease in the intensive care unit [manuscript published online ahead of print 29 August 2020]. Clin Infect Dis 2020; ciaa1298. doi:10.1093/cid/ciaa1298

103. Lier AJ, Tuan JJ, Davis MW, et al. Case report: disseminated strongyloidiasis in a patient with COVID-19. Am J Trop Med Hyg 2020; 103:1590–2.

104. Tham SM, Lim WY, Lee CK, et al. Four patients with COVID-19 and tuberculosis, Singapore, April-May 2020. Emerg Infect Dis 2020; 26:2764–6.

105. Zhang B, Zhang S. Corticosteroid-induced osteonecrosis in COVID-19: a call for caution. J Bone Miner Res 2020; 35:1828–9.

106. McNally GM, Lichtin LA, Liu J, et al. Re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing [manuscript published online ahead of print 25 August 2020]. Clin Infect Dis 2020; ciaa1275. doi:10.1093/cid/ciaa1275

107. To KK-W, Hung IF-N, Ip JD, et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing [manuscript published online ahead of print 29 August 2020]. J Viral Hepat 2020; doi:10.1111/jvh.13410

108. Frigault MJ, Nikiforow S, Mansour MK, et al. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 2020; 136:137–9.

109. Busani S, Bedini A, Biagioni E, et al. Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies [manuscript published online ahead of print 25 August 2020]. Clin Infect Dis 2020; ciaa1246. doi:10.1093/cid/ciaa1246

110. Rodriguez-Garcia JL, Sanchez-Nieves G, Seow CS, Chen W, Gulati Kansal M. Bowel ulceration following tocilizumab administration in a COVID-19 patient. BMJ Open Gastroenterol 2020; 7:e000484.

111. Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018; 131:121–30.

112. White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose coronavirus 2019–associated invasive fungal disease in the intensive care unit [manuscript published online ahead of print 29 August 2020]. Clin Infect Dis 2020; ciaa1298. doi:10.1093/cid/ciaa1298

113. Rodrigo-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy [manuscript published online ahead of print 24 September 2020]. J Viral Hepat 2020; doi:10.1111/jvh.13410

114. Tham SM, Lim WY, Lee CK, et al. Four patients with COVID-19 and tuberculosis, Singapore, April-May 2020. Emerg Infect Dis 2020; 26:2764–6.

115. Zhang B, Zhang S. Corticosteroid-induced osteonecrosis in COVID-19: a call for caution. J Bone Miner Res 2020; 35:1828–9.

116. Bruce-Hickman D, Saeed SM, Pang YH, Seow CS, Chen W, Gulati Kansal M. Bowel ulceration following tocilizumab administration in a COVID-19 patient. BMJ Open Gastroenterol 2020; 7:e000484.

117. To KK-W, Hung IF-N, Ip JD, et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing [manuscript published online ahead of print 25 August 2020]. Clin Infect Dis 2020; ciaa1275. doi:10.1093/cid/ciaa1275

118. Frigault MJ, Nikiforow S, Mansour MK, et al. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 2020; 136:137–9.

119. Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med 2020; 26:1691–3.

120. McCarthy CP, Murphy S, Jones-O’Connor M, et al. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine 2020; 26:1691–3.